Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Inhalation Sciences: Inhalation Research Services receives revised order with increased payment from US pharma company

Download the release

(Stockholm 18 October 2022) Inhalation Research Services (IRS) has received a revised order increasing the amount that it will be paid by a US pharma company. The original order, communicated on 18 July 2022, was for 136,000 Euro. This has now been raised to 151,000 Euro as additional steps within the research project have been contracted out to IRS by the client.

ISAB's world-class expertise in inhalation, and its high-precision IPL (Isolated Perfused Lung) ex vivo method, were decisive in the client's choice of IRS for research into a new repurposed drug being reformulated for administration via the lungs.

ISAB CEO Manoush Masarrat: "We are pleased with the confidence our client has shown in Inhalation Research Services and our technology."

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.